Korean Circ J.  2014 Jan;44(1):42-44. 10.4070/kcj.2014.44.1.42.

Myocardial Infarction Type 4b in Human Immunodeficiency Virus-Infected Patient

• Cybula-Walczak A
• Szymanski
• Platek AE
• Karpinski

• KMID: 1859241
• DOI: http://doi.org/10.4070/kcj.2014.44.1.42

Abstract

We report a case of a 52-year-old human immunodeficiency virus (HIV)-infected male patient receiving combined antiretroviral therapy (cART), who presented with acute ST-elevation myocardial infarction (STEMI). He was properly treated (e.g., prescribed anti-coagulation drugs: aspirin, clopidogrel, enoxaparin) and discharged. After 1.5 months, another STEMI related with in-stent thrombosis took place. The cART scheme was altered, resulting in no further cardiac events in the follow-up period, with undetectable levels of HIV ribonucleic acid. This case highlights the association between HIV infection and the specific drugs of cART, and the risk of cardiovascular disease development.

Keyword

Human immunodeficiency virus; Myocardial infarction; Antiretroviral therapy

MeSH Terms

Aspirin
Cardiovascular Diseases
Follow-Up Studies
HIV
HIV Infections
Humans*
Male
Middle Aged
Myocardial Infarction*
RNA
Thrombosis
Aspirin
RNA

Reference

1. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012; 33:2551–2567.

2. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009; 373:723–731.

3. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012; 13:453–468.

4. DAD Study Group. Friis-Møller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356:1723–1735.

5. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010; 170:1228–1238.

6. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008; 22:1389–1397.

7. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J. 2011; 32:945–951.

8. Boccara F, Lang S, Meuleman C, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol. 2013; 61:511–523.

9. Hrynkiewicz-Szymanska A, Szymanski FM, Filipiak KJ, et al. Can obstructive sleep apnea be a cause of in-stent thrombosis? Sleep Breath. 2011; 15:607–609.

10. Deeks SG, Gandhi RT, Chae CU, Lewandrowski KB. Case records of the Massachusetts General Hospital. Case 30-2012. A 54-year-old woman with HIV infection, dyspnea, and chest pain. N Engl J Med. 2012; 367:1246–1254.